 Other concerns include thoughts of suicide.According to the U.S. Drug Enforcement Administration (DEA), suvorexant produces similar reinforcing effects to those of zolpidem in humans and thus may have a similar abuse liability.As such, suvorexant has been designated a schedule IV controlled substance in the U.S. under the Controlled Substances Act.